|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q3 FY2016
As of Sep 30, 2016
|
Q2 FY2016
As of Jun 30, 2016
|
Q1 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q3 FY2015
As of Sep 30, 2015
|
Q2 FY2015
As of Jun 30, 2015
|
Q1 FY2015
As of Mar 31, 2015
|
Q4 FY2014
As of Dec 31, 2014
|
Q3 FY2014
As of Sep 30, 2014
|
Q2 FY2014
As of Jun 30, 2014
|
Q1 FY2014
As of Mar 31, 2014
|
Q4 FY2013
As of Dec 31, 2013
|
Q3 FY2013
As of Sep 30, 2013
|
Q2 FY2013
As of Jun 30, 2013
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment - net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| TOTAL | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued clinical expenses | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Accrued payroll and related costs | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Deferred revenue - noncurrent | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Preferred Stock | ||||||||||||||||||||
| Series X Contingently Redeemable Convertible Preferred Stock | ||||||||||||||||||||
| Contingently Redeemable Convertible Preferred Stock | ||||||||||||||||||||
| Series X Convertible Preferred Stock | ||||||||||||||||||||
| Total preferred Stock | ||||||||||||||||||||
| Stockholders' equity (deficit): | ||||||||||||||||||||
| Right granted to investors to purchase future shares of Series X-1 convertible preferred stock | ||||||||||||||||||||
| Common stock, $0.001 par value, 100,000,000 shares authorized; 26,179,302 and 13,854,491 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity (deficit) | ||||||||||||||||||||
| TOTAL | ||||||||||||||||||||
Loading...
